ArticlePulmonary circulation2026
A Congestive Hemodynamic Footprint Is Associated With Worse Clinical Outcomes in Lung Transplant Recipients.
Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Right heart catheterization (RHC) and echocardiography are integral in the assessment of pulmonary hypertension (PH) and cardiac function for lung transplant (LT) candidates. However, the impact of these metrics on post-LT outcomes remains unclear. We performed a single-center retrospective study of adult LT recipients from 2010 to 2022 to evaluate how RHC and echocardiographic variables relate to mortality, length of stay (LOS), duration of mechanical ventilation (MV), and rejection. An unsupervised cluster analysis was used to identify hemodynamic subgroups with adverse outcomes. Among 297 patients undergoing single or bilateral LT, most had interstitial lung disease (ILD; 52%), followed by chronic obstructive pulmonary disease (COPD; 32%) and other diagnoses (16%); mortality did not differ by indication (COPD 51%, ILD 37%, other 45%;
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.